SCHEMBL17877677

SCHEMBL17877677

O=C(N1CCC(O)(Cn2cnc3c(cnn3-c3ccc(F)cc3)c2=O)CC1)C(F)(F)F

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 18/20 0.67
SMN1; SMN2 Q16637 2/20 0.54
HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17870033 0.90 USP7 (0.70) USP7SMN1; SMN2
SCHEMBL17869117 0.89 USP7 (0.72) USP7SMN1; SMN2HTT
SCHEMBL17870400 0.88 USP7 (0.68) USP7SMN1; SMN2HTT
SCHEMBL19888832 0.88 USP7 (0.71) USP7
SCHEMBL17894634 0.88 USP7 (0.65) USP7SMN1; SMN2
SCHEMBL17869907 0.87 USP7 (0.68) USP7SMN1; SMN2
SCHEMBL17894723 0.87 USP7 (0.68) USP7
SCHEMBL17869131 0.87 USP7 (0.62) USP7SMN1; SMN2
SCHEMBL17894606 0.87 USP7 (0.65) USP7SMN1; SMN2
SCHEMBL17895033 0.86 USP7 (0.66) USP7SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9902728-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors FORMA THERAPEUTICS, INC. (US) 2018-02-27 US disclosed
WO-2016109515-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-07-07 WO disclosed
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2016-06-30 US disclosed
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, UBXN1 USP7 1/4885SMN1; SMN2 1782/4885HTT 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.